Related Experiment Video
Updated: May 13, 2025

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
Published on: July 16, 2014
Deep reinforcement learning for Type 1 Diabetes: Dual PPO controller for personalized insulin management
Alessandro Marchetti1, Daniele Sasso1, Federico D'Antoni2
1University Campus Bio-Medico of Rome, Via Alvaro del Portillo 21, Rome, 00128, RM, Italy.
Background:
Managing blood glucose levels in Type 1 Diabetes Mellitus (T1DM) is essential to prevent complications. Traditional insulin delivery methods often require significant patient involvement, limiting automation. Reinforcement Learning (RL)-based controllers offer a promising approach for improving automated insulin administration.
Methods:
We propose a Dual Proximal Policy Optimization (Dual PPO) controller for personalized insulin delivery in a hybrid closed-loop system. The controller optimizes patient-specific insulin bounds through a grid search on pre-trained models to manage both hyperglycemia and hypoglycemia. A safe-control mechanism prevents insulin administration when glucose levels drop below a predefined threshold. The system was evaluated on 10 in silico adult patients using the UVA/Padova simulator, with five-day randomized meal scenarios.
Results:
The Dual PPO controller significantly improved Time in Range (TIR) (69.30% ±1.61) compared to a single PPO model (61.69% ±1.54). The system effectively reduced severe hyperglycemia while maintaining a low incidence of severe hypoglycemia. Unlike conventional open-loop methods such as Basal-Bolus (BBC) and Proportional-Integral-Derivative (PIDC) controllers, our system requires minimal patient interaction, eliminating the need for carbohydrate estimation.
Conclusions:
The Dual PPO controller enhances personalized insulin delivery in T1DM, improving glycemic control while reducing patient burden. This approach advances precision medicine in diabetes management, with potential for future real-world applications.
More Related Videos
Related Concept Videos
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Type 2 and Gestational
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

